THOMAS JEFFERSON UNIVERSITY

Simon Ratliff appointed CEO of Dignity Health’s Bakersfield hospitals; Chris Woleske to retire from Emplify Health; Kert Anzilotti named president of ChristianaCare’s medical group; Joseph Hill becomes chief culture, equity and belonging officer at Cone Health.

Dr. Sara Szal Gottfried explains that stress responses like anxiety and anger can impact health if chronic, leading to issues like disrupted circadian rhythms, insomnia, and increased risk of heart attack. She suggests managing these emotions through awareness, controlled breathing, and meditation, while also recommending lifestyle changes such as reducing caffeine and alcohol intake.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

Christine M. Eischen, PhD, discussed developing a precision therapy for p53-mutated cancer using an anti-MDM2 PROTAC to activate p73, potentially leading to apoptosis. Further optimization is needed before clinical trials to test survival extension in p53-mutated cancer patients.

Becker's honors healthcare CNOs for tackling nurse staffing shortages, managing budgets, and developing professional growth opportunities. CNOs oversee nursing departments, spearhead innovative patient care initiatives, and bring clinical expertise and executive leadership skills. The list is based on nominations and editorial research, with leaders presented in alphabetical order.

EyePoint Pharmaceuticals has dosed the first patient in the Phase 3 LUGANO trial of Duravyu (EYP-1901) for wet AMD. Duravyu is a sustained delivery therapy using vorolanib, a selective tyrosine kinase inhibitor. The global, randomized, double-masked Phase 3 trials (LUGANO and LUCIA) aim to enroll 400 patients each, comparing Duravyu to aflibercept. Duravyu, administered every six months, could potentially revolutionize treatment by reducing the need for frequent injections.

Tranq dope withdrawal symptoms are severe, leading patients to leave hospitals prematurely. A new treatment approach using short-acting opioids and ketamine reduced discharge rates and withdrawal severity in Philadelphia.

Members of the US Pancreatic Disease Study Group include C. Mel Wilcox, Ji Young Bang, Akwi Asombang, Chloe Bennett, Yan Bi, Wojciech Blogowski, James Buxbaum, Wei-Shen Chin, Darwin Conwell, Gregory A. Coté, Timothy B. Gardner, Pramod Garg, Nalini Guda, Robert Hawes, Yasmin G. Hernandez-Barco, Emily Jonica, Prashant Kedia, Thomas Kowalski, Vivek Kumbhari, Linda Lee, Jorge Machicado, Desiree Morgan, Thiruvengadam Muniraj, Udayakumar Navaneethan, Veeral Oza, Swati Pawa, Rajesh Puri, Amit Rastogi, D. Nageshwar Reddy, Monica Saumoy, Mandeep Sawhney, Santhi Swaroop Vege, Rupjyoti Talukdar, Paul Tarnasky, Felix Tellez-Avila, Shyam Thakkar, Nikhil Thiruvengadam, Elaina Vivian, Irving Waxman, Field F. Willingham, Shyam Varadarajulu.